Last Update: Aug 20, 2026 A Phase II, Multicenter, Open-label, Single Arm Study to Evaluate the Safety and Efficacy of Asciminib in Pediatric Participants Newly Diagnosed or Previously Treated With Philadelphia Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) With or Without Known T315I Mutation ClinicalTrials.gov Identifier: [NCT07354074](https://clinicaltrials.gov/ct2/show/NCT07354074) Novartis Reference Number:CABL001I12202 [See if you Pre-qualify](#trial-eligibility "See if you Pre-qualify") All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. ## Study Description The aim of this study is to support development of asciminib in the pediatric population (1 to \\< 18 years) with Ph+ CML-CP. The study will evaluate the efficacy and safety of asciminib in pediatric formulation (weigh-based dose, fed state) or adult formulation (fasted) in newly diagnosed and resistant or intolerant Ph+ CML-CP with or without T315I mutation. This is a multi-center, open-label, single arm study of asciminib in pediatric participants aged 1 to \\<18 years old with Ph+ CML-CP newly diagnosed and previously treated with TKI treatment, with or without T315I mutation. The study population will consist of three cohorts of Ph+ CML-CP pediatric participants: \* Newly-diagnosed Ph+ CML-CP participants without known T315I mutation \* Ph+ CML-CP participants resistant or intolerant to previous TKI without known T315I mutation \* Ph+ CML-CP participants with known T315I mutation irrespective of prior TKI treatment There is no fixed duration of study treatment for the participants. The study will end 5 years (240 weeks) after the last enrolled participants received their first dose of treatment in the study. The objective is to have enough follow up for safety, including growth and development and efficacy. Condition Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive Phase Phase2 Overall Status Recruiting Number of Participants50 Start Date Apr 28, 2026 Completion Date Feb 23, 2033 Gender All Age(s) 1 Year - 18 Years (Child, Adult) ## Interventions Drug ### Asciminib single agent Asciminib (labelled as ABL001) administered as 40 mg tablet (adult formulation) or as 1 mg film-coated granules mini-tablets (pediatric formulation) ## Eligibility Criteria Key Inclusion Criteria: Participants eligible for inclusion in this study must meet all of the following criteria: 1\. Signed informed consent must be obtained prior to participation in the study. 2\. Male or female participants 1 and \\< 18 years of age at study enrollment 3\. Diagnosis of CML-CP (Apperley et al 2025) with cytogenetic confirmation of Philadelphia positive (Ph+) chromosome 4\. For participants with CML-CP newly diagnosed within 3 months of screening OR 5 For participants with CML - CP with high risk of developing resistance or intolerance to previous TKI: 1. Unfavourable response to TKI is defined following the Apperley et al 2025 guidelines as: \* At three months after the initiation of therapy: BCR::ABL1 ratio \\> 10% IS (if confirmed within 1-3 months) \* At six months after the initiation of therapy: BCR::ABL1 ratio \\> 10% IS \* At twelve months after initiation of therapy: BCR::ABL1 ratio \\> 1% IS \* At any time loss of previous response \* At any time emergent resistant BCR::ABL1 mutations or high-risk ACA from prior TKI treatment as per local test results 2. Intolerance to TKI is defined as: \* Non-hematologic intolerance: participants with grade 3 or 4 toxicity while on therapy (in which case the patient is eligible whether or not there was a dose reduction); or with persistent grade 2 toxicity unresponsive to optimal management including dose adjustments (unless dose reduction is not considered in the best interest of the patient if response is already suboptimal) \* Hematologic intolerance: participants with grade 3 or 4 toxicity (absolute neutrophil count \\\[ANC\\\] or platelets) while on therapy that is recurrent after dose reduction to the lowest doses of the TKI 6\\. Evidence of typical BCR::ABL1 transcript \\\[e14a2 and/or e13a2\\\] at the time of screening which are amenable to standardized RQ-PCR quantification. 7\\. Performance status: Karnofsky ≥ 50% for participants ≥ 16 years of age, and Lansky ≥ 50 for participants \\< 16 years of age at the time of screening. Key Exclusion Criteria: 1\. Known second chronic phase (CP) of CML after previous progression to Accelerated Phase (AP)/Blast Phase (BP). 2\. Previous treatment with a hematopoietic stem-cell transplantation. 3\. Patient planned to undergo allogeneic hematopoietic stem cell transplantation 4\. Known presence of a BCR::ABL1 mutation with known resistance to study treatment in accordance with the most recent public version of international CML clinical guidelines (e.g. NCCN CML treatment guidelines v 1.2026 and Apperley et al 2025) any time prior to study entry Other inclusion/exclusion criteria may apply. Australia #### Novartis Investigative Site Recruiting Brisbane,Queensland,4101,Australia #### Novartis Investigative Site Recruiting North Adelaide,South Australia,5066,Australia Brazil #### Novartis Investigative Site Recruiting São Paulo,São Paulo,04829-310,Brazil #### Novartis Investigative Site Recruiting Rio de Janeiro,Rio de Janeiro,20211-030,Brazil Canada #### Novartis Investigative Site Recruiting Montreal,Quebec,H3t 1c5,Canada #### Novartis Investigative Site Recruiting Edmonton,Alberta,T6g 1c9,Canada China #### Novartis Investigative Site Recruiting Tianjin,300020,China #### Novartis Investigative Site Recruiting Zhengzhou,Henan,450003,China France #### Novartis Investigative Site Recruiting Marseille,13885,France #### Novartis Investigative Site Recruiting Paris,75019,France #### Novartis Investigative Site Recruiting Strasbourg,67000,France #### Novartis Investigative Site Recruiting Poitiers,86021,France Germany #### Novartis Investigative Site Recruiting Erlangen,91054,Germany Italy #### Novartis Investigative Site Recruiting Roma,RM,00165,Italy Japan #### Novartis Investigative Site Recruiting Yokohama,Kanagawa,232-8555,Japan #### Novartis Investigative Site Recruiting Saitama,330 8777,Japan #### Novartis Investigative Site Recruiting Fukuoka,8128582,Japan Netherlands #### Novartis Investigative Site Recruiting Utrecht,3584 cs,Netherlands Poland #### Novartis Investigative Site Recruiting Gdansk,80-214,Poland #### Novartis Investigative Site Recruiting Wroclaw,50-556,Poland South Korea #### Novartis Investigative Site Recruiting Seoul,03080,South Korea #### Novartis Investigative Site Recruiting Seoul,06591,South Korea Spain #### Novartis Investigative Site Recruiting Madrid,28009,Spain #### Novartis Investigative Site Recruiting Barcelona,08035,Spain United States #### Seattle Childrens Hospital Recruiting Seattle,Washington,98105,United States ###### Todd Cooper ###### Angela Bleeker Phone: [206-884-1071](tel:206-884-1071) Email: #### Columbia University Medical Center New York Presbyterian Recruiting New York,New York,10032,United States ###### Nobuko Hijiya ###### Karishma Sookraj Phone: [212-305-6953](tel:212-305-6953) Email: #### Cinn Children Hosp Medical Center Recruiting Cincinnati,Ohio,45229-3039,United States ###### Benjamin Mizukawa ###### Lori Backus Email: #### Rutgers Cancer Institute of New Jersey Recruiting New Brunswick,New Jersey,08901,United States ###### Richard DRACHTMAN ###### Jesmin Habeeb Mohamed Email: ## Worldwide Contacts If the location of your choosing does not feature any contact detail, please reach out using the information below. #### Novartis Pharmaceuticals Phone: [ +41613241111](tel:+41613241111) Email: [](mailto:) #### Novartis Pharmaceuticals Phone: [ 1-888-669-6682](tel:1-888-669-6682) Email: